Home > Reports > CRISPR-Cas9 Gene Editing Technologies Market Outlook to 2026

CRISPR-Cas9 Gene Editing Technologies Market

CRISPR-Cas9 Gene Editing Technologies Market: Information by Application (Genome Engineering, Disease Models, RNA Editing & Knockdown), End Users, and Region — Forecast till 2026

Published On : 12 Jun, 2019
Updated On : 16 Sep, 2022
Table of Content Download Sample

Market Snapshot

Base Year:
2017
Study Period:
2016–2026
CAGR:
14.6 %
Fastest Growing Market:
Asia Pacific
Largest Market:
North America

Gene editing is the modern biotechnological technique designed to alter the genomes of living organisms for health or economic benefits. Nowadays, gene editing is not only used in the medical sector but also in the agricultural sector. CRISPR-Cas9 is a newly introduced and improved technology which effectively and specifically alter genes within organisms. CRISPR-Cas9 has found wide array of applications in biomedicine, disease modeling, RNA editing, and others. Constantly increasing demand for the technologically advanced products and technologies is the vital factor global CRISPR-Cas9 gene editing technologies market growth.

Increasing government funding for genomics projects and growing prevalence of hereditary diseases including Down Syndrome are the key driving factors for the global CRISPR-Cas9 gene editing technologies market. According to the World Health Organization (WHO), global prevalence rate of Down Syndrome is between 1 in 1000 to 1 in 1100. Moreover, as per the American Society of Hematology, every year more than 300,000 births suffer sickle cell disease. Rise in the application of genomics in medical field is the other factor which has positively influenced the global CRISPR-Cas9 gene editing technologies market. Gene editing and gene therapy is increasingly used in the sickle cell cure, cancer treatment, new skin building treatment, sight restoration, and hemophilia treatment.

Technological advancements regarding gene editing and increasing demand for genetically modified crops has fuelled the growth of the market. In March 2017, experimental gene therapy was used for the treatment of a patient suffering from sickle cell disease. The therapy resulted into astonishing development of normal red blood cells in the patient’s body.

However, gene editing and research is a brainstorming process and requires skilled professionals. Thus, lack of skilled professionals in the field of gene therapy is the key restraining factor for the market. Additionally, high cost of research and longer approval time for the technologies may hamper the market growth.

The global CRISPR and Cas9 gene editing market size was valued at USD 1,621.2 million in 2018 and is anticipated to reach USD 4907.7 million by 2026, at a CAGR of 14.6% from 2019 to 2026.

Get more information on this report Download Sample Report

Intended Audience

  • Gene Editing Technologies Manufacturer
  • Investor
  • Research & Development Professionals
  • Gene Therapy Manufacturer

Segmental Insights

The global CRISPR-Cas9 gene editing technologies market is segmented on the basis of applications and end users.

Based on application, the global market is segmented into genome engineering, disease models, RNA editing, knockdown/activation, and others. Genetic engineering is further segmented into medicine, agriculture, research, and others. Disease models is sub-segmented into oncology, cardiology, CNS, infectious diseases, dermatology, metabolic & genetic diseases, and others.

In terms of end users, the global market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and others.

Regional Analysis

The global CRISPR-Cas9 gene editing technologies market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.

CRISPR Cas9 Gene Editing Technologies Market Regional Analysis

Regional Growth Insights Request Sample Pages

North America dominates the global market. Well-developed technology, favorable government policies and increasing demand for new and advanced medical technologies for treatment of several chronic diseases are some of the key factors driving the market growth in the region. According to the American Cancer Society, over 1.7 million new cases of cancer were diagnosed with cancer in 2018 in the U.S. Increase in the prevalence of chronic disease in the region is the other factor fueling the market growth. As per the Leukemia & Lymphoma Society of Canada (LLSC), over 138,100 people in Canada suffered from blood cancer in 2016.

Europe accounts for significant share of the global market due to technological advancements regarding gene editing technologies and high adoption of the gene therapy technologies in the region. Gene therapy is highly adopted in the U.K as the number of people suffering from diseases which can be cured by gene editing is high. According to the Royal National Institute of Blind People, more than 350,000 people in the U.K were registered as blind or partially sighted. Adding that, this number is expected to rise to 4.1 million by 2050. Availability of the funds for research and development of the technologies and presence of the key players in the region are the other factors which are supporting the CRISPR-Cas9 gene editing technologies market.

Asia Pacific is the fastest growing market owing to presence of huge opportunity for the development of the market. Additionally, presence of rapidly growing economy has fuelled the market growth in this region.

On the other hand, the Middle East & Africa holds the least share in the market. Middle East holds the major share due to well-developed technology and high spending on research.

Top Key Players

List of key CRISPR-Cas9 gene editing technologies market companies profiled

  • Thermo Fisher Scientific (U.S.)
  • Merck & Co. Inc. (U.S.)
  • Genscript (U.S.)
  • Sangamo Therapeutics Inc. (U.S.)
  • Integrated DNA Technologies Inc. (U.S.)
  • Lonza (Switzerland)
  • New England Biolabs (U.S.)
  • CRISPR THERAPEUTICS (Switzerland)
  • Mirus Bio LLC (U.S.)
  • Takara Bio Inc. (Japan)
  • Abbott Laboratories (U.S.)
  • Bio-Rad Laboratories Inc. (U.S.)

Global CRISPR-Cas9 Gene Editing Technologies Market: Segmentation

By Application

  • Genome Engineering
    • Medicine
    • Agriculture
    • Research
    • Other
  • Disease models
    • Oncology
    • Cardiology
    • CNS
    • Infectious diseases
    • Dermatology
    • Metabolic and genetic diseases
    • Others
  • RNA editing
  • Knockdown/activation
  • Others

By End Users

  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Others

By Regions

  • North America (U.S and Canada)
  • Europe (Germany, France, Italy and Rest of Europe)
  • Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
  • LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Why Buy This Report Right Now?

In January 2019, Editas Medicine, a CRISPR genome editing medicine manufacturer announced plans for the development of its CRISPR based medicine which is in clinical trials phase II. The company is planning on initiating patient screening for its EDIT-101 experimental genome editing medicine for the treatment of Leber congenital amaurosis 10 (LCA10). This patient screening will be based on the patients in North America and Europe.

Global CRISPR/Cas9 gene editing technologies market is a booming market owing to the wide array of applications associated with the emerging gene editing CRISPR technology. The other factor mainly influencing the market growth is increase in the prevalence of several chronic diseases and various hereditary diseases. Research & development professionals focusing on the development of gene editing technologies and subsequent medicines is the factor supporting market growth across the globe.

Our report covers the fermented dairy market insights, focusing on recent developments in the market in different regions and development strategies of the companies. Moreover, following sections are specifically covered in the report.

  • Definitive Market Data
  • Market Analysis
  • Competitive Analysis
  • Recent Opportunities in the Market
  • Technological Advancements
  • 6-7 year performance forecasts: major segments covering top applications, end users and geographies
  • Market Share Analysis
  • Potential Venture Avenues

Frequently Asked Questions (FAQs)

The CRISPR-Cas9 Gene Editing Technologies Market is studied from 2019–2026.
The Market is growing at a CAGR of 14.6% during the forecast period, 2019–2026.
Asia Pacific is the largest market share in the Market is growing.
The end users mentioned in the Market report are Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Others.
Thermo Fisher Scientific, Merck & Co., Inc, Genscript, Sangamo Therapeutics, Inc, Integrated DNA Technologies, Inc, Lonza, New England Biolabs, CRISPR THERAPEUTICS
Report Metric Details
Market Size USD in Billion By 2030
CAGR CAGR 14.6%
Historical Data 2019-2020
Base Year 2021
Forecast Period 2022-2030
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered by Application (Genome Engineering, Disease Models, RNA Editing & Knockdown), By End Users
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Thermo Fisher Scientific (U.S.), Merck & Co., Inc. (U.S.), Genscript (U.S.), Sangamo Therapeutics, Inc. (U.S.), Integrated DNA Technologies, Inc. (U.S.), Lonza (Switzerland), New England Biolabs (U.S.), CRISPR THERAPEUTICS (Switzerland), Mirus Bio LLC (U.S.), Takara Bio Inc. (Japan), Abbott Laboratories (U.S.), and Bio-Rad Laboratories, Inc. (U.S.).
Key Market Opportunities Rapid Growth In Healthcare It Industry Enhances Crispr-Cas9 Gene Editing Technologies Market
Price Starts From
$4250

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers